{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:05:02Z","timestamp":1780556702634,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic uveal melanoma (UM) primarily affects the liver, and due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for hepatic tumor control. Direct head-to-head trials comparing these LDTs are still lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective multicenter explorative analysis was conducted to evaluate the clinical outcomes of transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT), and percutaneous hepatic perfusion (PHP, chemosaturation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The present analysis was conducted on a cohort of 121 patients who had been treated for metastatic UM with LDT at five different skin cancer centers. A total of n\u2009=\u200915 patients received TACE (12.4%), n\u2009=\u200951 SIRT (42.1%), and n\u2009=\u200955 PHP (45.5%). The estimated median overall survival (OS) for SIRT was 25.1\u2009months (95% confidence interval [CI], 15.3-34.8), for TACE, 11.4\u2009months (95% CI, 7.8-14.9), and for PHP, 24.9\u2009months (95% CI, 13.7-36.0). In the multivariate analysis that included LDH and additional systemic therapies, there was no significant difference in OS between SIRT and PHP (HR 1.14, 95% CI 0.67-1.93, P\u2009=\u2009.63), whereas TACE was found to be associated with a substantially reduced in OS compared to PHP (HR 3.25, 95% CI 1.31-8.04, P\u2009=\u2009.01). Adverse events occurred in 41.6% of patients undergoing SIRT, 64.3% of patients receiving TACE, and 84.6% of patients receiving PHP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of this study indicate that SIRT and PHP demonstrate equivalent survival rates in a real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag152","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:45:11Z","timestamp":1778154311000},"source":"Crossref","is-referenced-by-count":0,"title":["Selective internal radiotherapy and chemosaturation show equivalent survival in metastatic uveal melanoma: a retrospective multicenter study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2005-7533","authenticated-orcid":false,"given":"Elias A T","family":"Koch","sequence":"first","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU) , Erlangen, 91054,","place":["Germany"]},{"name":"Comprehensive Cancer Center Erlangen\u2014European Metropolitan Area of Nuremberg (CCC ER-EMN) , Erlangen, 91054,","place":["Germany"]},{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU) , Erlangen, 91054,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen , \u00d6stliche Stadtmauerstra\u00dfe 30 , Erlangen, 91054,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa A","family":"Schielein","sequence":"additional","affiliation":[{"name":"Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg , Heidelberg, 69120,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reitmajer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center for Dermatooncology, University Hospital T\u00fcbingen , T\u00fcbingen, 72076,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christine","family":"Glaser","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University of Cologne, Faculty of Medicine and University Hospital Cologne , Cologne, 50937,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Drexler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Regensburg , Regensburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Franklin","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University of Cologne, Faculty of Medicine and University Hospital Cologne , Cologne, 50937,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center for Dermatooncology, University Hospital T\u00fcbingen , T\u00fcbingen, 72076,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU) , Erlangen, 91054,","place":["Germany"]},{"name":"Comprehensive Cancer Center Erlangen\u2014European Metropolitan Area of Nuremberg (CCC ER-EMN) , Erlangen, 91054,","place":["Germany"]},{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU) , Erlangen, 91054,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen , \u00d6stliche Stadtmauerstra\u00dfe 30 , Erlangen, 91054,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C","family":"Hassel","sequence":"additional","affiliation":[{"name":"Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg , Heidelberg, 69120,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus V","family":"Heppt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU) , Erlangen, 91054,","place":["Germany"]},{"name":"Comprehensive Cancer Center Erlangen\u2014European Metropolitan Area of Nuremberg (CCC ER-EMN) , Erlangen, 91054,","place":["Germany"]},{"name":"Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU) , Erlangen, 91054,","place":["Germany"]},{"name":"Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen , \u00d6stliche Stadtmauerstra\u00dfe 30 , Erlangen, 91054,","place":["Germany"]},{"name":"Dermpath M\u00fcnchen, Laboratory for Dermatopathology, Oral Pathology and Molecular Pathology , Munich, 80335,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"German Dermatologic Cooperative Oncology Group (DeCOG, Committee Ocular Melanoma)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gschnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kreuzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Tomsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026060402352591400_oyag152-B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000480640","article-title":"Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013)","volume":"4","author":"Aronow","year":"2018","journal-title":"Ocul Oncol Pathol"},{"key":"2026060402352591400_oyag152-B2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/archopht.119.5.670","article-title":"Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15","volume":"119","author":"Collaborative Ocular Melanoma Study G","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"2026060402352591400_oyag152-B3","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026060402352591400_oyag152-B4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","article-title":"Immunotherapy in melanoma: recent advances and future directions","volume":"43","author":"Franklin","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"2026060402352591400_oyag152-B5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"key":"2026060402352591400_oyag152-B6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00262-021-03090-4 34709438","article-title":"Clinical determinants of long-term survival in metastatic uveal melanoma","volume":"71","author":"Koch","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2026060402352591400_oyag152-B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133359","article-title":"Immune checkpoint blockade for metastatic uveal melanoma: Patterns of response and survival according to the presence of hepatic and extrahepatic metastasis","volume":"13","author":"Koch","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026060402352591400_oyag152-B8","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026060402352591400_oyag152-B9","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026060402352591400_oyag152-B10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"2026060402352591400_oyag152-B11","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s11684-023-0993-y","article-title":"Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial","volume":"17","author":"Koch","year":"2023","journal-title":"Front Med"},{"key":"2026060402352591400_oyag152-B12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.hpb.2019.11.002","article-title":"Systematic review of liver directed therapy for uveal melanoma hepatic metastases","volume":"22","author":"Rowcroft","year":"2020","journal-title":"HPB (Oxford)"},{"key":"2026060402352591400_oyag152-B13","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","article-title":"Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study","volume":"28","author":"Meijer","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2026060402352591400_oyag152-B14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"key":"2026060402352591400_oyag152-B15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/COC.0000000000000033","article-title":"Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: Clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography","volume":"39","author":"Eldredge-Hindy","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"2026060402352591400_oyag152-B16","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2026060402352591400_oyag152-B17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00270-019-02177-x","article-title":"Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the delcath systems\u2019 Second-Generation hemofiltration system: a prospective non-randomized phase II trial","volume":"42","author":"Meijer","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026060402352591400_oyag152-B18","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2022.40.16_suppl.9510","article-title":"FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301\/301A)","volume":"40","author":"Zager","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026060402352591400_oyag152-B19","doi-asserted-by":"publisher","first-page":"8262","DOI":"10.1245\/s10434-024-15886-6","article-title":"Correction: Efficacy and safety of the melphalan\/hepatic delivery system in patients with unresectable metastatic uveal melanoma: results from an open-label, single-arm, multicenter Phase 3 study","volume":"31","author":"Zager","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026060402352591400_oyag152-B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204942","article-title":"Selective internal radiotherapy (SIRT) and chemosaturation percutaneous hepatic perfusion (CS-PHP) for metastasized uveal melanoma: a retrospective comparative study","volume":"15","author":"Kolb","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026060402352591400_oyag152-B21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12880-022-00887-2","article-title":"Analysis of patient\u2019s X-ray exposure in hepatic chemosaturation procedures: a single center experience","volume":"22","author":"Ebel","year":"2022","journal-title":"BMC Med Imaging"},{"key":"2026060402352591400_oyag152-B22","doi-asserted-by":"publisher","first-page":"e0314055","DOI":"10.1371\/journal.pone.0314055","article-title":"Correction: Percutaneous hepatic melphalan perfusion: single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery","volume":"19","author":"Struck","year":"2024","journal-title":"PLoS One"},{"key":"2026060402352591400_oyag152-B23","doi-asserted-by":"publisher","first-page":"e0254817","DOI":"10.1371\/journal.pone.0254817","article-title":"Percutaneous hepatic melphalan perfusion: single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery","volume":"16","author":"Struck","year":"2021","journal-title":"PLoS One"},{"key":"2026060402352591400_oyag152-B24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11247469","article-title":"Improved survival after transarterial radioembolisation for hepatocellular carcinoma gives the procedure added value","volume":"11","author":"Mosconi","year":"2022","journal-title":"J Clin Med"},{"key":"2026060402352591400_oyag152-B25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3390\/cancers17030495","article-title":"The relationship between response rate and survival benefits in randomized immunotherapy studies","volume":"17","author":"Jain","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026060402352591400_oyag152-B26","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jamaoncol.2015.6315","article-title":"Response rate as a regulatory end point in single-arm studies of advanced solid tumors","volume":"2","author":"Oxnard","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026060402352591400_oyag152-B27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"2026060402352591400_oyag152-B28","doi-asserted-by":"publisher","first-page":"CD004787","DOI":"10.1002\/14651858.CD004787.pub2","article-title":"Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma","volume":"2011","author":"Oliveri","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag152\/68259858\/oyag152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag152\/68259858\/oyag152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag152\/68259858\/oyag152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:35:35Z","timestamp":1780554935000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag152\/8675011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag152","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,8]]},"article-number":"oyag152"}}